Skip to main content

Branded

  • Walgreens expands Prescription Savings Club

    DEERFIELD Ill. — Walgreens on Tuesday infused greater value into its Prescription Savings Club program, which now offers discounts on more than 8,000 brand-name and generic prescriptions, thanks to the inclusion of more than 700 "value-priced" generics, which retail as low as $12 for a 90-day supply.

  • GSK to buy up research and development company

    LONDON — GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

    The British drug maker announced that it would buy the shares of Cellzome it doesn't already own for $99 million. Cellzome has labs in the United Kingdom and Germany, and will become part of GSK's research and development organization. The company, of which GSK currently owns 19.98%, develops technologies for profiling compounds in cells and patient samples.

  • AstraZeneca CEO David Brennan to step down

    LONDON — The head of drug maker AstraZeneca will retire next month, the company said.

    The Anglo-Swedish drug manufacturer announced the planned retirement of CEO and board member David Brennan, effective June 1.

    Executive director and CFO Simon Lowth will act as interim CEO following Brennan's departure, until a new CEO can be found, while VP group finance Julie Brown will become interim CFO.

  • Melanoma campaign enlists former football coach as spokesman

    NEW YORK — A former football coach is joining an effort to educate men about the risks of a deadly form of skin cancer.

    Former National Football League Pittsburgh Steelers coach Bill Cowher will work with Melanoma Exposed, an educational campaign run by the Melanoma International Foundation, Melanoma Research Alliance, Melanoma Research Foundation and the Skin Cancer Foundation, with sponsorship from drug maker Bristol-Myers Squibb, the organizations announced Tuesday.

  • FDA panel recommends approval for experimental Gilead HIV drug

    FOSTER CITY, Calif. — Gilead Sciences scored a second favorable Food and Drug Administration expert panel vote as the FDA's Antiviral Drugs Advisory Committee recommended on Friday that the regulatory agency approve an experimental drug designed to treat HIV.

  • Giant-Carlisle take-back event collects nearly 3 tons of unused drugs

    CARLISLE, Pa. — Giant Food Stores collected nearly 3 tons of unused medications during a nationwide medication take-back day last month, the chain said.

    Giant, owned by Dutch supermarket operator Ahold, said it and its Martin's Food Markets banner collected 5,843 lbs of unwanted and expired medications at 43 of its stores during the April 28 take-back event, doubling the amount collected last year.

  • Mylan marks Food Allergy Awareness Week

    BASKING RIDGE, N.J. — A company that makes an emergency treatment for severe allergic reactions is marking the 15th annual Food Allergy Awareness Week.

    Mylan Specialty, a division of drug maker Mylan, said it would support various initiatives to raise awareness of life-threatening food allergies during the special week, which started Sunday and ends Saturday. Mylan Specialty is the maker of EpiPen (epinephrine), used to treat anaphylaxis, a severe allergic reaction that can occur quickly and without warning.

  • Amgen offers testimony at FDA biosimilars hearing

    THOUSAND OAKS, Calif. — Biotech drug maker Amgen has joined the list of companies offering testimony at a Food and Drug Administration hearing on biosimilars Friday.

X
This ad will auto-close in 10 seconds